Connect with us

Technology

RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG CANCER

Published

on

Competitive CDMRP award funds preclinical programs against two cryptic cell-surface targets discovered directly in patient tumors using the company’s AI-powered RyboCypher™ platform and CypherAtlas™ knowledgebase

SAN DIEGO, July 9, 2026 /PRNewswire/ — RyboDyn, Inc., a biotechnology company decoding the dark proteome with an AI-powered sequencing and discovery platform, today announced a $1.3 million award from the U.S. Department of War (DOW) to advance preclinical development of two novel antibody-based therapies for lung cancer. The award will support the company’s antibody-drug conjugate (ADC) and T-cell engager (TCE) programs targeting two previously undiscovered cell-surface proteins identified directly from patient tumors through CypherAtlas™, RyboDyn’s integrated dark transcriptome and proteome atlas.

The award was made through the Congressionally Directed Medical Research Programs (CDMRP) Peer Reviewed Cancer Research Program (PRCRP) Impact Award, a highly competitive program that supports innovative approaches with the potential to significantly improve outcomes for cancer patients. The funding follows RyboDyn’s recent Seed financing and continued expansion of CypherAtlas™, now one of the largest integrated resources for cryptic cancer biology.

A target problem, not a molecule problem

Despite remarkable advances in AI, protein engineering, and antibody discovery, nearly 90% of oncology drugs entering clinical trials still fail to reach approval. In many cases, the limiting factor is not the quality of the therapeutic molecule, but the biology it is designed to target. The industry continues to pursue the same relatively small set of well-characterized targets. Those proteins are often present in only a subset of patients or are also expressed in healthy tissues, limiting efficacy, increasing toxicity, and leaving many patients without effective treatment options.

RyboDyn approaches drug discovery in reverse. Rather than beginning with known biology, the company starts with patients, mining thousands of tumors to identify previously hidden proteins that recur across large patient populations while remaining absent from healthy tissue. By discovering therapeutic targets directly from patient biology before drug design begins, RyboDyn aims to fundamentally improve the probability of developing first-in-class medicines.

Powered by an unprecedented atlas of hidden biology

At the core of RyboDyn’s discovery engine is RyboCypher™, which combines deep sequencing of non-canonical RNAs, proteomic validation, and foundational AI models to identify disease-specific therapeutic targets that conventional approaches cannot detect. Each discovery is integrated into CypherAtlas™, the company’s continuously expanding atlas of the dark transcriptome and dark proteome, now built from more than 2,000 patient samples spanning 12 oncology indications.

Today, CypherAtlas contains more than 6 million conserved, previously uncharacterized dark RNAs, over 80,000 cryptic peptides empirically identified by mass spectrometry, and approximately 10,000 cancer-specific peptides with therapeutic potential. Together, these data represent one of the richest collections of clinically relevant therapeutic targets assembled from the dark proteome and provide the foundation for RyboDyn’s growing pipeline of first-in-class therapeutic programs.

From atlas to assets

The prioritized targets emerged as two of the most prevalent cell-surface targets identified in lung cancer, making them particularly well suited for antibody-drug conjugate and T-cell engager development. Under the DOW award, RyboDyn will generate therapeutic candidates against both targets, characterize their biological activity, and advance the programs through in vivo proof-of-concept studies.

Why lung cancer remains a DOW priority

Lung cancer remains the leading cause of cancer death in the United States and disproportionately affects military service members and veterans. Exposure to burn pits, asbestos, diesel exhaust, Agent Orange, and other occupational hazards, together with historically higher smoking prevalence, has contributed to substantially elevated lung cancer risk within veteran populations. Approximately 8,000 veterans are diagnosed with lung cancer each year. By expanding the pool of novel therapeutic targets, RyboDyn’s approach aligns closely with the DOW’s mission to improve treatment options for service members, veterans, and the broader cancer community.

“This grant validates our belief that one of the greatest remaining opportunities in oncology is not simply building better drugs, but revealing biology that has always existed, yet remained inaccessible because of the limitations of conventional sequencing technologies. When we analyzed our first patient tumors with RyboCypher™, our highest-priority targets emerged almost immediately. As we expanded our analysis across larger patient cohorts, we confirmed that these targets recur broadly and consistently across patients. That is exactly the biology CypherAtlas™ was built to uncover, and the foundation for developing first-in-class medicines for the patients who need them most.”

About RyboDyn, Inc.

RyboDyn is redefining how diseases are targeted by decoding the dark proteome: cryptic proteins missed by conventional and next-generation sequencing. Powered by RyboCypher™, its proprietary RNA sequencing and AI-enabled discovery platform, the company identifies novel therapeutic targets directly from patient samples. By discovering highly prevalent, disease-specific targets before drug development begins, RyboDyn matches therapeutic opportunities to patient populations from the outset, enabling a differentiated path to first-in-class therapies for cancer and other diseases with significant unmet medical need. Built on intellectual property licensed from Oregon Health & Science University Knight Cancer Institute, RyboDyn is based at Lilly Gateway Labs in San Diego and is a member of Lilly’s AI TuneLabs consortium and NVIDIA’s Inception Program. The company also maintains a publicly disclosed collaboration with Moffitt Cancer Center. RyboDyn is backed by Genedant, SeaX Ventures, SOSV, Swell VC, Massive Tech Ventures, and P2V.

Media Contact

Andy Bass
VP, Corporate Strategy
info@rybodyn.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rybodyn-awarded-1-3m-dow-grant-to-advance-novel-antibody-therapies-for-lung-cancer-302821583.html

SOURCE RyboDyn

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

RecordPoint launches global partner program as AI adoption drives surge in data governance demand

Published

on

By

New channel-first strategy gives resellers, consultancies and systems integrators a route into the fastest-growing budget line in regulated IT

SEATTLE, July 10, 2026 /PRNewswire/ — RecordPoint, the global data and AI governance platform, today announced the launch of its Global Partner Program, a formal channel program enabling partners to resell, co-sell and refer RecordPoint’s technology to their customers.

The launch marks a strategic shift to a channel-first business model for RecordPoint, designed to help partners capitalise on rapidly growing demand for data and AI governance as organisations scale AI adoption.

“Every regulated organisation deploying AI right now is discovering the same thing: you cannot govern AI without first governing your data,” RecordPoint CEO Anthony Woodward said.

“Data governance and AI governance have converged into a single conversation in every boardroom. AI is only as trustworthy as the data underneath it, and that realisation has turned data governance from a compliance line item into one of the fastest-growing budget priorities in enterprise IT.”

The program offers two tracks. A reseller track spans four tiers — Aggregator, Certified, Select and Premier — with the entry-level Aggregator tier carrying no revenue requirement and handling software procurement and fulfilment, while higher tiers unlock greater margins in line with increasing revenue commitments. A parallel referral and co-sell track allows partners to work alongside RecordPoint’s own sales teams. All partners complete technical and sales certifications before transacting, ensuring customers receive consistent expertise across the ecosystem.

RecordPoint positions itself as complementary to, not competitive with, its partners’ services businesses: the platform is RecordPoint’s, while configuration, file plans and the client relationship remain the partner’s to own.

The program will be led by Christian Lucarelli, VP Global Partner Sales & Strategy, who joined RecordPoint in January from process intelligence and automation vendor Nintex, where he spent nearly a decade in senior leadership roles, most recently heading the company’s global partner program.

“We’ve built this program so partners can monetise the data and AI governance opportunity from day one,” Lucarelli said. “Certified enablement, deal registration, joint marketing and a customer book of named logos partners can lead with — the infrastructure is all there.”

To support the program, RecordPoint is launching a new partner portal alongside dedicated enablement tracks covering sales, commercial, technical and delivery skills. The company has also committed partner marketing funds and co-branding resources, with deal registration and access to Microsoft’s co-sell motion available to participating partners.

Woodward said the move reflects how buying behaviour has changed. “Organizations don’t want to buy point software anymore. They want a partner who can advise on their entire data and AI strategy. RecordPoint provides the technology layer, and our partners bring the consulting, frameworks and implementation services that wrap around it. Together, that’s the complete offering regulated organizations are asking for.”

“We’ve reached the scale where the channel is the right lever to accelerate growth,” Woodward added. “Our partners get a platform purpose-built for the conversation their customers are already having, backed by fifteen years of authority running the data lifecycle inside the world’s most regulated organizations.”

The program serves organizations globally including national and regional systems integrators, specialist data and information governance consultancies, managed service providers, Microsoft 365 and cloud advisory firms, and Big 4 advisory practices.

Learn more and register for RecordPoint’s Partner Program launch and first Quarterly Partner Update on 23 July:

RecordPoint Quarterly Partner Update – July 2026 (APAC) Webinar

RecordPoint Quarterly Partner Update – July 2026 (NA) Webinar

You can also apply for the program at recordpoint.com/partner.

About RecordPoint

Founded in 2009 and headquartered in Sydney, RecordPoint is a global data-trust platform that enables organizations to discover, govern and control their information across systems, clouds and repositories. The platform provides AI-driven classification, regulatory compliance, lifecycle management and defensible disposal at enterprise scale. RecordPoint serves leading financial services institutions, government agencies and regulated industries worldwide.

View original content:https://www.prnewswire.com/news-releases/recordpoint-launches-global-partner-program-as-ai-adoption-drives-surge-in-data-governance-demand-302821861.html

SOURCE RecordPoint

Continue Reading

Technology

WYF Launches Global AI Talent Compact at AI for Good Global Summit 2026

Published

on

By

GENEVA, July 10, 2026 /PRNewswire/ — World Youth Forum (WYF), an international nonprofit advancing challenge-based learning and youth development across more than 30 countries, today launched the Global AI Talent Compact at the AI for Good Global Summit 2026 in Geneva, where WYF served as an official session partner.

The summit, organized by the International Telecommunication Union (ITU) in partnership with more than 50 UN agencies and co-convened with the Government of Switzerland, is the United Nations’ leading platform on artificial intelligence.

The Compact establishes an open global action network built on five commitments: expanding access to AI literacy; defining the human capabilities that matter most in the AI era; scaling real-world, challenge- and project-based learning; safeguarding youth well-being; and recognizing ability through evidence of real work, not credentials alone.

“AI is changing not only how young people learn and create, but how talent is identified and recognized,” said Houston Hou, Global Executive Convener of WYF. “Young people need pathways through which real ability can be seen, trusted and connected. The Compact is an open invitation to build those pathways together.”

The launch convened leaders from across the UN system, academia and youth innovation, including Fabrizio Hochschild, former UN Under-Secretary-General; Frédéric Werner, Head of Strategic Engagement, AI for Good, ITU; and Ben Nelson, Chairman and CEO of Minerva Project. Alongside speakers from AI Singapore (AISG), the ASEAN Foundation, the International Trade Centre (ITC), the United Nations Research Institute for Social Development (UNRISD), the United Nations University (UNU), and student AI communities including the Imperial AI Group, the Oxford Guild, the University of Toronto Machine Intelligence Student Team (UTMIST) and the Global AI Alliance at Penn. The Global SDGs and Leadership Development Center served as supporting partner of the session.

Following the launch, WYF will convene founding supporters worldwide — universities, student AI societies, education and innovation organizations, and industry partners — to advance year-round, challenge-based AI learning, new forms of talent recognition, and pathways connecting young talent with real-world opportunities.

About World Youth Forum

WYF is an international nonprofit youth development platform. Through educational programmes, competitions, international conferences and youth-led initiatives, WYF engages more than 500,000 young people annually across more than 30 countries.

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/wyf-launches-global-ai-talent-compact-at-ai-for-good-global-summit-2026-302822886.html

SOURCE World Youth Forum (WYF)

Continue Reading

Technology

UK mid-market growth masks stagnation, reveals Price Bailey

Published

on

By

LONDON, July 10, 2026 /PRNewswire/ — Price Bailey’s Mid-Market index shows revenue growth barely keeping pace with inflation as profits come under pressure.

UK mid–market companies are delivering headline revenue growth, but for most businesses this is barely outpacing inflation and is failing to translate into stronger profits, according to new research by Price Bailey, the leading accountancy firm. 

The Price Bailey Mid–Market Index 2026, which analysed 12,625 UK businesses with revenues between £10m and £250m across 16 sectors, found that average revenue growth continues to be driven by a small number of high–performing outliers rather than broader growth. 

While mean compound annual revenue growth stands at 12%, the median business is growing at just 6%, only slightly ahead of average inflation of 5.3% over the period. This gap highlights the pressure facing mid–market companies operating in a challenging economic environment. 

The research goes on to show that revenue growth across UK regions remains modest for the typical business, with median growth only marginally above inflation in most areas. London displays the widest gap between top–performing companies and the median. 

Sector analysis suggests that the strongest performers are businesses with the ability to protect or increase prices, those sectors with limited pricing flexibility are more likely to see growth eroded by inflationary pressures. 

According to the data, revenue growth is not feeding through into profit growth. EBITDA and profit after tax for mid–sized companies have failed to keep pace with rising revenues in recent years, meaning many businesses are working harder simply to stand still. This trend has implications for shareholders and business owners, as higher turnover does not necessarily equate to improved returns. 

Commenting on the findings, Chand Chudasama, member of the Board and Partner in the Strategy and Corporate Finance team at Price Bailey says: “The headline figures suggest growth, but when you look beneath the surface a different picture emerges. For many mid–market businesses, revenue increases are being absorbed by inflation and cost pressures, while profits remain stubbornly flat. The real differentiator now, is pricing power.” 

More data is available on in the Price Bailey Mid-Market Index, on the Price Bailey website.

 

View original content:https://www.prnewswire.co.uk/news-releases/uk-midmarket-growth-masks-stagnation-reveals-price-bailey-302822895.html

Continue Reading

Trending